International safety notice
Adakveo (crizanlizumab) – No superiority of crizanlizumab over placebo
Ireland / HPRA · IRL · Feb 14, 2023
Key facts
| Title | Adakveo (crizanlizumab) – No superiority of crizanlizumab over placebo |
|---|---|
| Regulator | Ireland / HPRA |
| Country | IRL |
| Brand | Adakveo (crizanlizumab) – No superiority of crizanlizumab over placebo |
| Models | SUSTAIN1, NCT03814746, STAND2, NCT01895361, SELG1, CSEG101A2301, 2080612, CSEG101A2201 |
| Date | Feb 14, 2023 |
At a glance
- No Recall
- No Field safety notice
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About International device safety notices
Field safety notices, recalls and safety alerts published by about 30 national medical device regulators outside the United States, matched by Orca1 to FDA device data.
Source: National medical device regulators (as listed), compiled by Orca1